Bioavailability of aspirin in fasted and fed states of a novel pharmaceutical lipid aspirin complex formulation

• Published in: Journal of thrombosis and thrombolysis Vol. 49; no. 3; pp. 337 - 343
• Main Authors: Angiolillo, Dominick J., Bhatt, Deepak L., Lanza, Frank, Deliargyris, Efthymios N., Prats, Jayne, Fan, Weihong, Marathi, Upendra
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2020; Springer Nature B.V
• Subjects: 01244100; Administration, Oral; Adult; Aspirin; Aspirin - administration & dosage; Aspirin - pharmacokinetics; Bioavailability; Bioequivalence; Biological Availability; Cardiology; Cross-Over Studies; Fasting - blood; Female; Food; Food-Drug Interactions; Hematology; Humans; Lipids - administration & dosage; Lipids - pharmacokinetics; Male; Medicine; Medicine & Public Health; Metabolites; NCT01244100; Salicylic acid; Aspirin; Platelet; Bioavailability; Fasted; Fed; Pharmacokinetic
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-020-02051-5

Dyspeptic symptoms are common with aspirin and clinicians frequently recommend that it be taken with food to reduce these side effects. However, food can interfere with absorption, especially with enteric-coated aspirin formulations. We evaluated whether food interferes with the bioavailability of a new, pharmaceutical lipid-aspirin complex (PL-ASA) liquid-filled capsule formulation. In this randomized, open label, crossover study, 20 healthy volunteers fasted for ≥ 10 h and then randomized as either “fasted”, receiving 650 mg of PL-ASA, or as “fed”, with a standard high-fat meal and 650 mg of PL-ASA 30 min later. After a washout of 7 days, participants crossed over to the other arm. The primary outcome was comparison of PK parameters of the stable aspirin metabolite salicylic acid (SA) between fasted and fed states. Mean age of participants was 36.8 years and 55% were male. The ratios for the fed to fasted states of the primary SA PK parameters of AUC 0−t and AUC 0−∞ were 88.7% and 88.8% respectively, with 90% confidence intervals between 80 and 125%, which is consistent with FDA bioequivalence guidance. Mean peak SA concentration was about 22% lower and occurred about 1.5 h later in the fed state. Food had a modest effect on peak SA levels and the time required to reach them after PL-ASA administration, but did not impact the extent of exposure (AUC) compared with intake in a fasted state. These data demonstrate that PL-ASA may be co-administered with food without significant impact on aspirin bioavailability. Clinical Trial Registration: http://www.clinicaltrials.gov Unique Identifier: NCT01244100